Nanjing Jiqun Pharmaceutical Technology

Nanjing Jiqun Pharmaceutical Technology is a biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics and high-end generic drugs. The company's research efforts are primarily focused on metabolic disorders, cardiovascular diseases, and oncology. Jiqun's lead clinical program, JQ-001, is a selective URAT1 inhibitor designed to treat hyperuricemia and gout by promoting uric acid excretion. Beyond its internal pipeline, the company leverages its integrated R&D platform to provide pharmaceutical technology services and high-quality generic formulations. Jiqun Pharmaceutical aims to address significant unmet medical needs through a combination of internal innovation and strategic manufacturing capabilities.